RAPT Therapeutics Inc

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibits the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist being investigated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc., changed its name to RAPT Therapeutics, Inc. in May 2019, was incorporated in 2015, and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.